NCT00777296View on ClinicalTrials.gov

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2007

Primary Completion Date

February 27, 2008

Study Completion Date

February 27, 2008

Conditions

Cystic Fibrosis

Interventions

DRUG

ARIKACE™

Study start date is before Jan 18, 2017.

DRUG

Placebo

Study start date is before Jan 18, 2017.

Trial Locations (11)

Unknown

Leuven

Budapest

Kaposvár

Skopje

Rabka-Zdrój

Warsaw

Belgrade

Bratislava

Košice

Kharkiv

Kiev

All Listed Sponsors

lead

Insmed Incorporated

INDUSTRY

NCT00777296 - Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) | Biotech Hunter | Biotech Hunter